Guangxi LiuYao Group News

Guangxi LiuYao Group (603368): Tripartite cooperation to promote the implementation of the "AI + Medical" full-scenario application plan, with potential new applications both inside and outside the hospital.

Event: On March 11, Guangxi LiuYao Group, Huawei, and Shanghai Runda Medical Technology held a seminar on the "AI+Healthcare" full scenario application solutions at Guangxi LiuYao Group's Nanning campus. The three parties discussed promoting AI medical large models throughout the entire medical diagnosis and treatment process in the Hospital, both inside and outside.

Cinda SecuritiesMar 13 18:07

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 3 10:09

Express News | Guangxi LiuYao Group: The company has reached a Global Strategy cooperation with Huawei Cloud and Shanghai Runda Medical Technology.

BreakingsFeb 20 16:03

Guangxi LiuYao Group (603368.SH): Some fundraising investment projects have been completed and the surplus fundraising will be permanently used to supplement working capital.

On December 13, Gelonghui announced that Guangxi LiuYao Group (603368.SH) reported the completion and readiness for the "Nanning Traditional Chinese Medicine Decoction Piece Capacity Expansion Project" and the "Chain Pharmacy Expansion Project," which are part of the public issuance of convertible corporate bonds fundraising investment projects (hereinafter referred to as "fundraising projects"). The "Supplementary Working Capital" has been fully utilized. The company will conclude the aforementioned fundraising projects. To meet the demand for working capital for daily production and operation activities, the company plans to use the remaining fundraising funds totaling 57.2102 million yuan (the actual amount will be based on the balance of the fundraising special account on the day of the fund transfer).

Gelonghui FinanceDec 13, 2024 18:49

Not recognized by the capital markets? Guangxi Liuyao Group: The company's stock price does not match its value | Direct coverage of the earnings conference.

1. At the earnings conference, the chairman of guangxi liuyao group, Zhu Chaoyang, stated that the company's market cap, stock price, and company value are not aligned; 2. The company secretary Xu Yang stated that the company will improve the issue of high accounts receivable through measures such as strengthening the assessment of collection indicators for business personnel; 3. Xu Yang introduced the progress of the company's AI application business in response to investors' concerns.

cls.cnDec 9, 2024 20:31

Guangxi Liuyao Group (603368): The three major business segments are gradually improving, accelerating expansion outside the province.

Event: In the third quarter of 2024, guangxi liuyao group achieved revenue of 5.351 billion yuan, a year-on-year increase of 1.49%; achieved net income attributable to the parent of 0.252 billion yuan, a year-on-year increase of 8.68%; in the first three quarters of 2024, achieved revenue

caitong securitiesOct 30, 2024 19:32

Guangxi Liuyao Group Co., Ltd. Report for the Third Quarter of 2024

SZSIOct 30, 2024 00:00 · Announcements

Guangxi Liuyao Group (603368.SH) released its performance for the first three quarters, with a net income of 0.716 billion yuan, a year-on-year increase of 6.13%.

Guangxi Liuyao Group (603368.SH) disclosed the third quarter report of 2024, achieving a revenue of 15...

Zhitong FinanceOct 29, 2024 17:15

Guangxi Liuyao Group (603368.SH): The net income for the first three quarters was 0.716 billion yuan, a year-on-year increase of 6.13%.

格隆汇October 29th - Guangxi Liuyao Group (603368.SH) released its third quarter report, with revenue for the first three quarters reaching 15.99 billion yuan, a year-on-year increase of 2.41%, net income of 0.716 billion yuan, a year-on-year increase of 6.13%, non-net profit of 0.7 billion yuan, a year-on-year increase of 5.20%, and basic earnings per share of 1.87 yuan.

Gelonghui FinanceOct 29, 2024 16:38

Guangxi Liuyao Group (603368.SH): 36.8421 million shares of restricted shares will be lifted on October 24th.

Guangxi Liuyao Group (603368.SH) announced that the total number of stocks listed this time is 36.8421 million shares. The stock listing date is October 24, 2024.

Gelonghui FinanceOct 18, 2024 17:12

Guangxi Liuyao Group (603368.SH): As of August 31, 2024, the production capacity of traditional Chinese medicine formula granules has reached 1000 tons.

Guangxi Liuyao Group (603368.SH) announced that the company's traditional chinese medicine formulation granule project capacity: the total planned capacity of the project is 3,000 tons, with an initial capacity of 1,500 tons. From January to August 2024, the company actively promoted equipment introduction, process optimization, and equipment technological upgrading to accelerate capacity improvement. As of August 31, 2024, the capacity of the traditional chinese medicine formulation granule project reached 1,000 tons, effectively meeting the company's market expansion needs. At the same time, the company further accelerated capacity follow-up based on market development progress to ensure the company's supply advantages of traditional chinese medicine formulation granules. The company has a variety of traditional chinese medicine formulation granule varieties.

Gelonghui FinanceSep 12, 2024 16:12

CP smart home AI health services will be launched this year. Guangxi Liuyao Group: The new online settlement policy is conducive to improving the current high accounts receivable situation. | Direct hit earnings conference

At the earnings conference, Chairman Zhu Chaoyang of Guangxi Liuyao Group introduced the progress of the company's AI scenario application business. For the high accounts receivable, the company's CFO Zeng Xiangxing stated that the company has adjusted its operational strategy and strengthened the collection efforts. Guangxi Liuyao Group also responded to the slight decline in growth of the pharmaceutical wholesale sector and issues related to the expansion of pharmaceutical new retail business.

cls.cnSep 11, 2024 20:30

Vice President Tang Xianrong of Guangxi Liuyao Group (603368.SH) reduced his shareholding by 0.02 million shares at the end of the shareholding period.

Guangxi Liuyao Group (603368.SH) announced that Vice President Tang Xianrong passed away on June 28, 2024 through centralized...

Zhitong FinanceSep 11, 2024 17:24

Guangxi Liuyao Group (603368): The growth rate of its distribution business has slowed down, waiting for improvements in the industry.

Event: In the first half of 2024, Guangxi Liuyao Group achieved a revenue of 10.642 billion yuan, a year-on-year growth of 2.88%; achieved a net income attributable to shareholders of 0.464 billion yuan, a year-on-year growth of 4.79%. The pharmaceutical wholesale business has been affected by policies and has made some adjustments.

財通證券Aug 29, 2024 19:16

Guangxi Liuyao Group Co., Ltd. 2024 Semi-Annual Report Report

SZSIAug 29, 2024 00:00 · Announcements

Guangxi Liuyao Group Co., Ltd. 2024 Semi-Annual Report Report Summary

SZSIAug 29, 2024 00:00 · Announcements

Guangxi Liuyao Group (603368.SH):

Guangxi Liuyao Group (603368.SH) announced its semi-annual report for 2024 on August 28th. During the reporting period, the company achieved revenue of 10.642 billion yuan, a year-on-year increase of 2.88%; net income attributable to shareholders of the listed company was 0.464 billion yuan, a year-on-year increase of 4.79%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.456 billion yuan, a year-on-year increase of 4.27%; basic earnings per share was 1.24 yuan.

Gelonghui FinanceAug 28, 2024 15:49

Express News | Guangxi Liuyao Group: net income was 0.464 billion yuan in the first half of the year, a year-on-year increase of 4.79%.

BreakingsAug 28, 2024 15:48

Express News | guangxi liuyao group: net income in the first half of 2024 was 0.464 billion yuan, a year-on-year increase of 4.79%.

BreakingsAug 28, 2024 15:39

Express News | Guangxi Liuyao Group: net income in the first half of the year increased by 4.79% year-on-year.

BreakingsAug 28, 2024 15:38